This California-Based Biotech Found Massive Success Following DSMB Approval

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, January 14, 2025

A California-based biotech company is turning heads during Tuesday’s session after the company announced its phase 2b COVID-19 trial received Independent Data Safety Monitoring Board (DSMB) approval and will expand its testing to 10,000 participants, according to a press release.

Traders were quick to snatch up shares of Vaxart Inc. (Nasdaq:VXRT), pushing the small cap up to $0.83/share (+15.25%) at the early session high. This move coincides with quite a few biotechs that have been finding success since over the last month or so.

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.